Snapshot

company: Chemist4U (legal entity Innox Trading Ltd) - UK online pharmacy/healthcare retailer HQ'd in Skelmersdale, Lancashire
sells: Prescription medicines (NHS + private), weight-loss injections (GLP-1s: Wegovy, Mounjaro), OTC medicines, vitamins and health & beauty products from mainstream brands
category: Multi-channel online pharmacy / marketplace-selling healthcare retailer (source-and-sell - buys stock from pharma wholesalers, resells to consumers)
model: Multi-channel D2C retail: own site chemist-4-u.com (Shopify-adjacent) + own app + Amazon UK storefront + Amazon US storefront + TikTok Shop + NHS prescription service. GPhC-registered, LegitScript-accredited, NHS-licensed
size activity: Revenue £128m latest year (up from ~£67m - double-digit growth all sectors). Pre-tax profit £3.6m (up from £1.7m). ~240 employees incl. 60 pharmacy-trained. New 40,000 sq ft Skelmersdale site + £6.5m automated warehouse. Actively hiring across ecommerce, warehouse and pharmacy
ownership: Founder-led - CEO/co-founder James O'Loan + co-founder Shamir Patel (both pharmacists). £12m growth investment from Pitalia Capital (2023)
footprint: Skelmersdale HQ + 40,000 sq ft automated fulfilment; ships nationally UK; also listed on Amazon US
sector: Health & beauty / online pharmacy - a Storfund category-2 sweet spot (beauty adjacent, high-frequency, fast-moving)
marketplace channels: Amazon.co.uk (merchant A04722913M0KZ4SG4OQMF), Amazon.com (merchant AC4G8Z4TRGGGB), TikTok Shop (@chemist4u), own D2C site
buyer profile: Founder-CEO + Head of Ecommerce (role open) - under the founder-led buying pattern for a £5-50M brand; Finance Director on the money side of settlement-cycle drag
contact: James O'Loan (CEO, LinkedIn cited); Shamir Patel (co-founder); incoming Ecommerce Manager will be a champion but not the budget-holder

All recent triggers

Revenue growth from ~£67m to £128m in latest reported year; pre-tax profit up £1.7m -> £3.6m - the classic scaling-seller cash-crunch window source
Multi-marketplace presence: live seller storefronts on Amazon.co.uk, Amazon.com and TikTok Shop, plus own D2C - every one of those channels holds settlement 10-21+ days source
Active hiring beyond the ecommerce role - Picking Team Leader, Goods-In Team Leader, Remote Pharmacist - signals warehouse throughput scaling, i.e. more upfront stock being purchased against slow marketplace payouts source
£6.5m automated warehouse + 40,000 sq ft site + workforce growth 120 -> 150+ (later 240+) - a capex + inventory expansion cycle that pulls cash forward
£12m Pitalia Capital growth investment (Sept 2023) - investor-backed growth mandate, KPI-driven on GMV and channel expansion source

Pain hypotheses

Marketplace payout drag on high-ticket GLP-1 units: Wegovy/Mounjaro carry high per-unit stock cost, and Amazon holds proceeds ~15-21 days (DD7 stretches further). Every extra day is inventory dollars locked out of the next re-order.
Multi-currency, multi-marketplace exposure: Amazon UK + Amazon US + TikTok Shop each with different payout cycles - makes cash forecasting for procurement complicated.
Pharmacy wholesaler credit lines are relatively short (30-day terms are the ceiling, not the norm) - so the cash cycle between paying the wholesaler and receiving marketplace settlement is a genuine working-capital squeeze, especially as they scale.
Growth capex commitments (£6.5m automated warehouse, new HQ, workforce doubling) mean less headroom cash to absorb settlement-cycle drag - classic PE-backed growth-vs-liquidity tension.
TikTok Shop specifically has been a growth channel for them (their @chemist4u presence is active) - TikTok Shop payout timing is unpredictable relative to Amazon.

Personalisation hooks

Founder-led + pharmacist-CEO: the story lands better as a peer note about how fellow scaling multi-marketplace UK operators are freeing up cash on TikTok Shop + Amazon settlement, not a lender pitch (which O'Loan would rightly ignore).
GLP-1 economics is the ideal wedge - high-ticket, high-velocity, upfront pay-for-stock, cash-tight, and the segment they publicly credit for growth. Framing: 'you're the one funding Amazon's 21-day float on Mounjaro'.
Ecommerce Manager hire is the tactical champion inside - but the actual buyer of a receivables-purchase mechanism is either James (founder-CEO) or the FD/Head of Finance. Play the ecom hire as an intro, target the founder + FD.
Pitalia-backed = board KPIs on growth + cash efficiency. A receivables-purchase (off-balance-sheet) is materially cleaner than a debt facility for an investor-backed scaleup.

ICP-fit score

62/100
Clears the 58 gate at 62 - not a blowout, but a solid ICP fit with defensible sourcing. Positive weight: (1) real UK source-and-sell reseller (buys from pharma wholesalers, resells) - NOT a manufacturer with long lead times, (2) verified live on Amazon UK, Amazon US, TikTok Shop simultaneously - classic multi-marketplace payout-gap exposure, (3) growth phase - £67m -> £128m in a year, £6.5m warehouse capex, active operational hiring, (4) founder-led + PE-backed (Pitalia £12m) - a decision-maker Storfund can reach and a board that cares about cash-efficient growth, (5) GLP-1 (Mounjaro/Wegovy) upfront-pay-for-stock economics is the sharpest possible wedge. Held down by: (a) £128m rev is above the sweet-spot midpoint - they are big enough to have a real Finance function already, so the play is FD-led not founder-led, (b) health-adjacent / regulated - some receivables-purchase structuring nuance around prescription-medicine SKUs may need review with Storfund credit, (c) the hire is a mid-level ecom role, not a Finance hire - so the champion isn't the buyer. Net: worth an outbound conversation, but pitch to the CEO + Finance Director, not the incoming Ecom Manager.

Recommended play

Peer, founder to founder reframe: 'you're on Amazon UK + Amazon US + TikTok Shop - that's ~15 21 days of every shipment's cash sat with the marketplace. Have you looked at what a next day receivables purchase does to your re order cycle on GLP 1s?' Value first (resource/benchmark), no meeting pitch in email 1. buyer unaware - Storfund's whole thesis (marketplace holds your cash) is not something a growing pharmacy CEO has framed as a solvable structural problem, they've just been living with it · category demand-creation, not head-to-head - Chemist4U almost certainly hasn't seriously evaluated Wayflyer/Uncapped etc. because they see themselves as a pharmacy, not a marketplace seller
Chemist4U hits multiple ideal-fit criteria at once - UK founder-led source-and-sell reseller, multi-marketplace, growth phase, scaling on a high-ticket high-velocity SKU category, PE-backed with cash-efficiency KPIs. Only pull-back: £128m rev puts them in the upper end of the ICP (largest Storfund customer is £12-13M/mo on one marketplace so still in-range, but this is more Head of Finance/FD outbound than sole-trader founder outbound).

Sources

adzuna.co.uk · chemist-4-u.com · amazon.co.uk · amazon.com · tiktok.com · chemistanddruggist.co.uk · uk.finance.yahoo.com · uk.linkedin.com · uk.linkedin.com